Table 4.
Raw data for all participants at baseline, after 6 months of TES and at 12 months
| Participant | Visit | Baseline | 6 Months | 12 Months | |||
| P1 | BCVA (letters) | C=88 | T=0.650 | C=84 | T=88 | C=86 | T=83 |
| GVF (sr) | C=1.000 | T=88 | C=1.059 | T=0.816 | C=1.407 | T=1.075 | |
| MP (db) | C=25.1 | T=24.0 | C=25.1 | T=25.5 | C=25.7 | T=23.5 | |
| IPT (mA) | T=0.3 | T=0.35 | T=0.3 | ||||
| P2 | BCVA (letters) | C=59 | T=60 | C=60 | T=58 | C=60 | T=60 |
| GVF (sr) | C=0.099 | T=0.101 | C=0.139 | T=0.131 | C=0.136 | T=0.138 | |
| MP (db) | C=3.1 | T=2.7 | C=3.1 | T=3.4 | C=6.1 | T=3.4 | |
| IPT (mA) | T =>1.0 | T=0.3 | T=0.85 | ||||
| P3 | BCVA (letters) | C=88 | T=86 | C=79 | T=84 | C=84 | T=85 |
| GVF (sr) | C=2.628 | T=3.431 | C=2.592 | T=3.158 | C=2.265 | T=2.697 | |
| MP (db) | C=9.0 | T=2.8 | C=8.5 | T=2.7 | C=1.8 | T=7.0 | |
| IPT (mA) | T=0.55 | T =>1.0 | T=0.55 | ||||
| P4 | BCVA (letters) | C=82 | T=80 | C=88 | T=85 | C = * T = * | |
| GVF (sr) | C=0.736 | T=0.606 | C=0.963 | T=0.742 | |||
| MP (db) | C=27.5 | T=27.0 | C=27.0 | T=27.7 | |||
| IPT (mA) | T=0.08 | T=0.18 | |||||
| P5 | BCVA (letters) | C=52 | T=60 | C=56 | T=61 | C=54 | T=62 |
| GVF (sr) | C=0.112 | T=0.150 | C=0.149 | T=0.176 | C=0.152 | T=0.160 | |
| MP (db) | C=0.7 | T=0.5 | C=0.4 | T=0.9 | C=1.7 | T=1.1 | |
| IPT (mA) | T=0.6 | T=0.4 | T=>1.0 | ||||
| P6 | BCVA (letters) | C=75 | T=76 | C=70 | T=69 | C=73 | T=67 |
| GVF (sr) | C=0.076 | T=0.109 | C=0.082 | T=0.165 | C=0.093 | T=0.100 | |
| MP (db) | C=0.8 | T=2.7 | C=0.6 | T=1.3 | C=0.6 | T=0.7 | |
| IPT (mA) | T=0.25 | T=0.55 | T=0.35 | ||||
| P7 | BCVA (letters) | C=6 | T=53 | C=15 | T=62 | C=14 | T=56 |
| GVF (sr) | C=0.599 | T=0.545 | C=0.943 | T=0.988 | C=1.082 | T=0.842 | |
| MP (db) | Poor fixation | Poor fixation | Poor fixation | ||||
| IPT (mA) | T=0.58 | T=0.80 | T=0.85 | ||||
| P8 | BCVA (letters) | C=68 | T=26 | C=68 | T=30 | C = * T = * | |
| GVF (sr) | C=0.149 | T=0.183 | C=0.105 | T=0. 208 | |||
| MP (db) | C=4.0 | T=4.6 | C=6.2 | T=7.1 | |||
| IPT (mA) | T=0.09 | T=0.37 | |||||
| P9 | BCVA (letters) | C=81 | T=81 | C=89 | T=80 | C=81 | T=83 |
| GVF (sr) | C=1.600 | T=1.963 | C=2.330 | T=2.963 | C=2.188 | T=3.288 | |
| MP (db) | C=10.1 | T=13.9 | C=9.7 | T=16.0 | C=7.6 | T=15.2 | |
| IPT (mA) | T=0.32 | T=0.38 | T=0.42 | ||||
| P10 | BCVA (letters) | C=88 | T=88 | C=88 | T=89 | C=82 | T=84 |
| GVF (sr) | C=2.877 | T=2.402 | C=3.585 | T=3.272 | C=2.892 | T=3.399 | |
| MP (db) | C=18.1 | T=17.2 | C=18.4 | T=17.5 | C=17.1 | T=16.0 | |
| IPT (mA) | T=0.22 | T=0.19 | T=0.13 | ||||
| P11 | BCVA (letters) | C=77 | T=56 | C=76 | T=70 | C=72 | T=65 |
| GVF (sr) | C=1.118 | T=2.558 | C=1.723 | T=2.458 | C=1.557 | T=2.684 | |
| MP (db) | C=15.9 | T=16.7 | C=17.8 | T=16.0 | C=16.0 | T=14.2 | |
| IPT (mA) | T=0.45 | T=0.30 | T=0.32 | ||||
| P12 | BCVA (letters) | C=75 | T=72 | C=77 | T=66 | C=72 | T=67 |
| GVF (sr) | C=2.633 | T=1.415 | C=2.377 | T=2.482 | C=1.843 | T=1.646 | |
| MP (db) | C=7.7 | T=4.0 | C=2.2 | T=0.9 | C=0.9 | T=0.0 | |
| IPT (mA) | T=0.16 | T=0.23 | T=0.56 | ||||
| P13 | BCVA (letters) | C=88 | T=84 | C=88 | T=85 | C=89 | T=88 |
| GVF (sr) | C=1.157 | T=1.684 | C=0.951 | T=1.310 | C=1.173 | T=1.491 | |
| MP (db) | C=16.7 | T=18.1 | C=18.5 | T=18.1 | C=18.5 | T=17.9 | |
| IPT (mA) | T=0.77 | T=0.82 | T=0.73 | ||||
| P14 | BCVA (letters) | C=88 | T=87 | C=87 | T=85 | C=89 | T=87 |
| GVF (sr) | C=0.481 | T=0.187 | C=0.458 | T=0.235 | C=0.497 | T=0.294 | |
| MP (db) | C=14.5 | T=17.1 | C=15.9 | T=19.0 | C=19.1 | T=16.1 | |
| IPT (mA) | T=0.43 | T=0.45 | T=0.25 | ||||
IPT was only conducted on the treated eye.
* =*Not available, participant withdrawn.
BCVA, best-corrected visual acuity; C, control eye; GVF, Goldmann visual fields; IPT, individual phosphene threshold; MP, microperimetry; T, treated eye.